Introduction
============

Each year, more than 200,000 women are diagnosed with ovarian cancer. Ovarian cancer is the 8^th^most common cancer in women and the 2^nd^most common type of gynecological cancer in the world. In the USA, the prevalence of ovarian cancer in postmenopausal women is 1 in 2,500 and the lifetime risk of a woman developing ovarian cancer is 1 in 72. The age-adjusted incidence and death rates for ovarian cancer are 13.3 and 8.8 per 100,000, respectively. The average five-year survival rate for ovarian cancer patients is \~46%. This high overall mortality is a consequence of a failure to detect this disease at an early stage. As there are no clinically overt early symptoms, most women (\~75%) are first diagnosed with disseminated disease (Stage III/IV) when prognosis is poor. Despite recent progress in chemotherapeutic treatments, the diagnosis of late stage disease is associated with a five-year survival rate of \~30%. In contrast, when ovarian cancer is identified at an early stage, five year survival increases to \~90%. Thus, the development of more accurate and earlier detection tests for this disease are undoubtedly the number one priority for achieving long-term reduction of mortality from ovarian cancer \[[@B1]\].

Currently, plasma or serum CA125 concentration is the best characterised and most widely used ovarian cancer biomarker and is elevated in more than 80% of patients with epithelial ovarian cancer \[[@B2]\]. CA125 concentrations, however, are increased in only \~ 50% of patients with Stage I disease \[[@B3]\]. Thus, more accurate and earlier detection tests are requisite to reducing the mortality associated with this disease.

Previously, we and others have reported the utility of combining biomarkers to develop classification algorithms for identifying women with ovarian cancer \[[@B4]-[@B10]\]. Such studies establish proof-of-concept and the potential to improve diagnostic efficiency by combining multiple ovarian cancer biomarkers. The sensitivity and specificity of such panels, however, must be further improved and additional informative biomarkers that contribute to multivariate modelling need to be identified.

The purpose of this study was to characterise changes in the plasma concentrations of MDK in association with ovarian cancer and compare its diagnostic performance (as assessed by the AUC) with that of AGR2 (a recently reported circulating biomarker of ovarian cancer \[[@B11]\]) and CA125 in symptomatic women. Available data are consistent with a putative role for both AGR2 and MDK in oncogenesis and tumor progression, including ovarian cancer.

Materials and methods
=====================

Control and ovarian cancer plasma samples
-----------------------------------------

Plasma samples were collected from healthy women (median age 52, range 32-69 years, n = 61) and women at the time of diagnosis of ovarian cancer and before treatment (median age 61, range 24-69 years, n = 46). The project was approved by the Mercy Hospital for Women Human Research and Ethics Committee (R09/06). All case samples and part of the control sample set used in this study were provided by the Biobank at Peter MacCallum Cancer Research Institute (Melbourne, Australia) and all subjects participated in the study after signing an informed written consent. Blood (10 ml) was collected via vena puncture into EDTA vacutainer tubes and samples were centrifuged at 1000 g for 10 min within 20-30 min of collection. Plasma was stored as 250-1000 μl aliquots at -80°C until assayed. Ovarian tumor classification was based on the FIGO staging system, however, no stage IV tumors were identified for inclusion in this study.

Study Design
------------

The study was a retrospective, case-control design (*i.e.*a phase 2 biomarker trial \[[@B12]\] involving 107 plasma samples (see Table [1](#T1){ref-type="table"}) obtained from 61 controls and 46 cases (*i.e.*women previously diagnosed with ovarian cancer). Inclusion and exclusion criteria are presented in Table [2](#T2){ref-type="table"}. The primary outcomes of the study were: quantification of plasma concentrations of ir MDK and evaluation of its diagnostic performance (as defined by AUC); and comparison with AGR2 and CA125 concentrations measured in the same cohort. In addition, the contribution for these biomarkers to multi-analyte classification models was determined.

###### 

Distribution of Ovarian Tumor Types and Stages of ovarian cancer patients used for plasma AGR2 and CA125 measurements.

                        All Tumors   Stage I   Stage II   Stage III   Unstaged
  --------------------- ------------ --------- ---------- ----------- ----------
  **Serous**            29           3         17         9           
                                                                      
  **Mucinous**          5            1         3          1           
                                                                      
  **Endometrioid**      4            2         2                      
                                                                      
  **Clear Cell**        2                      1                      1
                                                                      
  **Mixed Mullerian**   3            1         2                      
                                                                      
  **Untyped**           3            2         1                      
                                                                      
  **Total**             46           9         26         10          1

###### 

Inclusion and exclusion criteria for inclusion of patient samples in the study.

  Inclusion Criteria                                                                                            Exclusion Criteria
  ------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  Age 18-80                                                                                                     Chemotherapy, biologic therapy or any other investigational drug for any reason within 28 days prior to sampling.
                                                                                                                
  Newly diagnosed, histologically or pathologically confirmed diagnosis of epithelial carcinoma of the ovary.   Except for cancer-related abnormalities, patients should not have unstable or pre-existing major medical conditions.
                                                                                                                
  No NSAID or prednisone use within 14 days of sampling.                                                        Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to sampling
                                                                                                                
  No previous chemotherapy or radiation therapy.                                                                Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to sampling
                                                                                                                
  No concurrent disease(s)                                                                                      Serious, non-healing wound, ulcer, or bone
                                                                                                                
  Signed informed client consent                                                                                

Biomarker Quantitation
----------------------

Plasma concentrations of MDK were quantified by sandwich ELISA assay (Peprotech, Rocky Hill, NJ, USA) that utilises rabbit antibodies raised to human midkine for both capture and detection stages of the assay. The assay was performed in Costar half-well immunoassay plates (Corning) coated with 50 μl of capture antibody at a concentration of 1 ug/ml in 50 mM carbonate buffer and incubated at 4°C for 18 h. Following four washes in PBS/Tween20 (Sigma), the plate was blocked with 150 μl/well of 0.1% BSA (Sigma) in PBS, for one hour at room temperature. Plasma samples diluted 1:2 in PBS containing 0.05% Tween20 and 0.1% BSA were applied to the plate following blocking, alongside a standard curve, from 2000 pg/ml down in doubling dilutions, constructed from a stock recombinant midkine. Samples and standards were incubated (50 μl/well) at room temperature for 2 h following which the plate was washed a further three times with wash buffer. Detection of bound midkine was made using 50 μl/well of biotinylated detection antibody at a concentration of 1.0 ug/ml for 2 h at room temperature. Following a further four washes the plate was incubated with a 1:2000 dilution of avidin-HRP conjugate for 30 min. Finally the plate was washed four times and 100 μl of OPD substrate added to the wells and incubated for 30 min in the dark. Prior to reading on a Multiskan Ascent the reaction is topped by addition of 25 μl of 3 M sulphuric acid.

AGR2 concentrations were quantified using an in-house sandwich ELISA employing a mouse monoclonal antibody (7A10) to a peptide epitope (KPGAKKDTKDSRPKL) of AGR2 that displays no measurable cross reactivity with AGR3, as previously reported \[[@B11]\].

CA-125 was quantified using Roche CA-125 Elecsys II assay (Roche, Mannheim, Germany, LD = 0.6 U/ml; intra- and inter-assay coefficients of variation CV = 3.3% and 4.3%) as previously reported \[[@B8]\].

Statistical Analyses
--------------------

Two sample group comparisons of median values were assessed by Mann Whitney tests (STAT 9.2, Stata Corporation, College Station, TX, USA). Correlation between two sample groups was assessed by Spearman\'s rank correlations using the Bonferoni correction). Multiple group comparisons were assessed by Kruskal-Wallis tests \[[@B13]\]. Dunn\'s tests \[[@B14]\] were used for post-hoc two sample comparisons. A p value of \< 0.05 was ascribed as statistically significant.

Multivariate Modelling
----------------------

Binomial classification algorithms were generated, based upon biomarker data obtained in this study, using a boosted logistic regression algorithm with Weka Data Mining Software (Ver 3-6-1, \[[@B15],[@B16]\]). The predicted posterior probability values reported (*i.e.*the likelihood that a sample came from a woman with ovarian cancer, that is ρP) were used to generate receiver operator characteristic curves. Sensitivity and specificity were calculated based on the numbers of correctly and incorrectly classified samples. For classification of samples based on conventional plasma CA-125 concentrations, a threshold value of ≥ 35 U/ml was used as indicative of ovarian cancer.

ROC Curve Comparisons
---------------------

For individual biomarkers, plasma concentration data were used to generate ROC curves (MedCalc, MedCalc Software bvba, Mariakerke Belgium). AUCs were calculated using the Wilcoxon statistic \[[@B17]\]. The diagnostic performance of the biomarkers was assessed by comparison of the area under ROC curves using the method of Hanley and McNeil \[[@B18]\] for ROCs derived from the same cases. A threshold value of 0.500 was used for classification of samples based on ρP. Values of \> 0.500 being classified as ovarian disease and samples with a calculated value \< 0.500 being classified as normal.

Results
=======

Cohort Characteristics
----------------------

The median age (range) of the control and case cohort were 52 years (32 - 69, n = 61) and 61 years (24 - 81, n = 46), respectively. The distribution of type and stage of ovarian cancer within the case cohort is presented in Table [1](#T1){ref-type="table"}. Of the cases included in this study, 76% (*i.e.*35 cases) were early stage disease (*i.e.*Stages I and II). The median CA125 plasma concentrations were 13 U/ml (range 3 - 84) for controls and 502 U/ml (5 - 10,209) for cases. In 3 controls, CA125 concentration was ≥ 35 U/ml. In 6 cases, CA125 concentration was \< 35 U/ml. At a threshold of 35 U/ml, the sensitivity and specificity of CA125 were 87.0 and 95.1%, respectively.

Variation with Disease State, Stage and Tumor Type
--------------------------------------------------

The variation in plasma analyte concentrations for control and case cohorts is presented in Figure [1](#F1){ref-type="fig"}. Median plasma concentrations of immunoreactive MDK, AGR2 and CA125 were significantly greater in the case cohort (909 pg/ml, 765 pg/ml and 502 U/ml, respectively n = 46) than in the control (383 pg/ml, 188 pg/ml and 13 U/ml, respectively n = 61) cohort (p \< 0.001, as assessed by Mann Whitney tests). Within control or case cohorts, plasma concentrations of AGR2 displayed no significant correlations with either CA125 or midkine concentrations (as assessed by Spearman\'s correlation, p \> 0.05). Within the case cohort, MDK plasma concentrations significantly correlated with CA125 concentrations (ρ = 0.383, p \< 0.01). Data were further analysed with respect to tumor type and Stage (Table [3](#T3){ref-type="table"}). No statistically significant effects of either tumor type or stage on biomarker plasma concentrations were identified (Kruskal-Wallis one-way analysis of variance, p \> 0.05).

![**Plasma biomarker concentrations**. The median plasma concentration within each group (normal women (controls) n = 61 and women with ovarian cancer (cases) n = 46) is represented by the horizontal line. Biomarker concentrations were significantly greater in case cohorts (solid symbols) when compared to their respective control cohort (open symbols) (p \< 0.001, Mann Whitney tests). Data are presented as log (plasma concentration). CA125 as U/ml; and MDK and AGR2 as pg/ml.](1756-9966-29-62-1){#F1}

###### 

Case cohort variation in plasma analyte concentration by stage of disease and tumor type, as assessed by Kruskal-Wallis One Way Analysis of Variance (Stage and Tumor Type).

  Analyte   **Stage n = 45**^**\#**^**(p)**   **Tumor Type n = 43**^**†**^**(p)**
  --------- --------------------------------- -------------------------------------
  MDK       0.722                             0.839
                                              
  AGR2      0.776                             0.334
                                              
  CA125     0.524                             0.214

\# 1 sample was unstaged

† 3 samples were not typed

Receiver Operator Characteristic Curve Analysis and Multi-analyte Modelling
---------------------------------------------------------------------------

ROC curves were generated for each individual analyte. The area under the curve (AUC) for MDK, AGR2 and CA125 was: 0.753 ± 0.049; 0.768 ± 0.048; 0.934 ± 0.027, respectively (AUC ± SEM). There was no significant difference between the AUC for midkine and AGR2. The AUC for CA125 was significantly greater than that for both midkine and AGR2 (p \< 0.001, Table [4](#T4){ref-type="table"}).

###### 

Comparison of AUC for MDK, AGR2, CA125 and multi-analyte panel Data represent AUC ± standard errors (SEM).

  Analyte                   AUC ± SEM       p
  ------------------------- --------------- ----------
  CA125                     0.934 ± 0.027   
                                            
  MDK                       0.753 ± 0.049   \< 0.001
                                            
  AGR2                      0.768 ± 0.048   = 0.001
                                            
  Multi-analyte Algorithm   0.988 ± 0.011   = 0.038

The difference in the AUC of MDK, AGR2 and the multi-analyte algorithm are compared to that of CA125. The AUC of MDK was not statistically significantly different from the AUC of AGR2 (p \> 0.05).

A binomial classification algorithm was developed by subjecting the observed plasma concentrations for MDK, AGR2 and CA125 to stochastic gradient boosted logistic regression analysis \[[@B19]\]. A ρP value was calculated for each patient set of biomarkers and used to generate a ROC curve (Figure [2](#F2){ref-type="fig"}). The AUC for the multi-analyte panel (0.988 ± 0.011) was significantly greater than that for MDK (p \< 0.001), AGR2 (p = 0.001) and CA125 (p = 0.038) (Figure [3](#F3){ref-type="fig"}). The sensitivity and specificity of the multi-analyte algorithm were 95.2 and 97.7%, respectively. Within the study cohort, CA125 displayed a sensitivity and specificity of 87.0 and 94.6%, respectively.

![**Predicted posterior probability values (ρP)**. Values were generated by multivariate modelling for each patient set of biomarkers for Case and Control cohorts.](1756-9966-29-62-2){#F2}

![**ROC curve comparison**. ROC curves are displayed for the multi-analyte algorithm (midkine, AGR2 and CA125) and CA125 alone. The AUC (± SEM) for the multi-analyte panel (black diamond) (0.988 ± 0.010) was significantly greater than that of CA125 alone (black circle) (0.934 ± 0.030, p = 0.035).](1756-9966-29-62-3){#F3}

Discussion
==========

The aims of this study were: to characterise and compare plasma concentrations of midkine (MDK) in normal healthy women with concentrations observed in women with ovarian cancer; and to establish and compare the performance of MDK with that of anterior gradient 2 protein (AGR2) and CA125 in the development of multi-analyte classification algorithms for ovarian cancer. A retrospective, case-control study was conducted to compare the diagnostic performance (as measured by AUC) of plasma ir MDK and ir AGR2 individually or in combination with CA125 with the performance of CA125 alone. Biomarker plasma concentrations were quantified in normal healthy women and women with confirmed ovarian cancer. The data obtained confirm the utility of both MDK and AGR2 as plasma biomarkers for ovarian cancer and, when combined in a multi-analyte panel, significantly improve the diagnostic efficiency of CA125.

The median plasma concentrations of both ir MDK and ir AGR2 were significantly greater in women with ovarian cancer (909 pg/ml and 765 pg/ml, respectively n = 46) than in normal healthy women (383 pg/ml and188 pg/ml, respectively n = 61) (p \< 0.001). There is a paucity of data characterising the plasma concentrations of MDK in ovarian cancer patients. Salama *et al.*(2006) \[[@B20]\] reported a similar change in serum MDK concentrations in 15 women with ovarian carcinoma (*i.e.*\> 500 pg/ml) and 49 controls (*i.e.*\< 500 pg/ml) to those concentrations reported in this study. Within the present study cohort, plasma concentrations of MDK and AGR2 were not significantly altered by tumor type or stage of disease. It is of note, however, that plasma concentrations of MDK and AGR2 display differential responsiveness in women with ovarian cancer when compared to CA125. In the case cohort, plasma concentrations of MDK but not AGR2 correlated significantly with CA125 concentrations. The lack of correlation between AGR2 and CA125 and AGR2 and midkine plasma concentrations in women with ovarian cancer may provide an opportunity to improve diagnostic efficiency by reducing the false negative rate and may be reflective of stage and/or tumor type- differential expression of AGR2 and CA125. This study, however, was not designed to definitively assess the relationship between analyte plasma concentration and disease stage and type and a larger cohort study would be required to resolve these relationships.

The diagnostic utility of MDK and AGR2 was further demonstrated by ROC curve analysis. It is acknowledged that good risk prediction models have an AUC \> 0.7 \[[@B21]\]. The AUCs for MDK and AGR2 were 0.753 and 0.768, respectively. Individually, neither MDK nor AGR2 was superior to the classification efficiency of CA125 alone. In combination with CA125, however, MDK and AGR2 significantly increased AUC by more than 0.05 to greater than 0.98. Within the study cohort, the increased diagnostic efficiency of the multi-analyte algorithm reduced false positive and false negative rates by more than 50% when compared with CA125 alone. The sensitivity and specificity of the multi-analyte algorithm was 95.2 and 97.7%, respectively. It is of note that the performance of the three analyte algorithm developed in it this study, at least, is comparable to that of previously reported algorithms containing a greater number of biomarkers (*e.g.*\[[@B8]\]).

The involvement of both MDK and AGR2 in oncogenesis and tumor progression has been previously reported. MDK is a 13-kDa secreted heparin-binding growth factor \[[@B22],[@B23]\], first identified in 1988 \[[@B24]\] and recent implicated in cell proliferation and survival, migration and angiogenesis \[[@B25]-[@B31]\]. Furthermore, MDK expression is induced in association with oncogenesis, inflammation and wound healing \[[@B32],[@B33]\] and is over-expressed in various human cancers, including ovarian cancer \[[@B34]-[@B38]\] and may contribute to the development of chemotherapy drug resistance \[[@B39]\].

Anterior Gradient 2 protein is the protein product of a proto-oncogene (7p21.3) implicated in cell migration, differentiation and proliferation and is over-expressed in cancer of various origins. In human breast cancer cells, AGR2 expression correlates positively with estrogen receptor \[[@B40]\] and negatively with epidermal growth factor receptor expression \[[@B41]\]. These data are consistent with the hypothesis that AGR2 may play a role in the differentiation of hormonally responsive breast cancers \[[@B40],[@B42]\]. More recently, a role for AGR2 in the aetiology of ovarian epithelial cancer has been proposed. AGR2 gene expression is significantly increased in ovarian carcinomas, particularly in mucinous tumors \[[@B43]\]. In non-neoplastic ovarian epithelial tissue, immunoreactive (ir) AGR2 was not detectable, however, virtually all ovarian tumors of variable histotypes stain positively for irAGR2. In addition, AGR2 has been reported to be released into the circulation of ovarian cancer patients \[[@B11]\]. Previous studies have reported that overexpression of AGR2 may promote the development of metastatic phenotype in benign breast cancer cell \[[@B42]\] and secreted AGR2 has been implicated in promoting proliferation of pancreatic cell lines in culture \[[@B44]\]. In addition, circulating tumor cells from patients with advanced metastatic disease display elevated AGR2 gene expression \[[@B45]\] suggesting that AGR2 may play a functional role in metastasis or may represent a useful biomarker of circulating tumor cells \[[@B46]\].

Conclusion
==========

The data obtained in this study confirm that the measurement of plasma concentrations of MDK and AGR2 individually display utility as biomarkers for ovarian cancer and that when included in a multi-analyte panel may significantly improve the diagnostic utility of CA125 in symptomatic women.
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